Tuesday, October 6, 2020

Risk-based agreements: Good for business, patients

When managed effectively—and supported by ample collaboration and data exchange—risk-based models promote better business results for practices by achieving better outcomes for patients.

____________________________________


Practices are questioning whether to accept risk-based contracts more than ever before. Even before COVID-19 hit, there was a clear slowdown in adoption of value-based care contracts. A recent Medicare Payment Advisory Commission report to Congress stated that only 517 accountable care organizations (ACOs) participated in the Shared Savings Program in 2018—down 44% from its height.


As the COVID-19 pandemic has deepened the financial and psychological challenges for practices, the idea of taking on the risk of a value-based care model may seem like an incredibly high hurdle in the current climate. Yet this is precisely the time to appreciate the substantial benefits that risk-based agreements offer both patients and practices.

When constructed properly, risk-based agreements reward practices that double-down on care management strategies that improve patient outcomes and stabilize practice reimbursement as they lower overall health costs. That’s because unlike traditional fee-for-service (FFS) models that reimburse based on service volume, risk agreements’ compensation structure pays practices for proactively managing key clinical factors and patient conditions, such as diabetes or smoking habits.


By focusing on outcomes, practices must also embrace and address the impact that social determinants of health (SDoH) have on a patient's health. The impact of SDoH on overall patient outcomes has been dramatically illustrated and exacerbated during the pandemic. People with the means to work from home and self-isolate, for example, have fared better than those required to work on-site in places where social distancing difficulties increase the risk of coronavirus exposure.

Even before COVID-19, however, many studies showed connections between SDoH factors, such as food insecurity and access to transportation, and a higher risk of costly conditions such as diabetes and cardiovascular disease. The incentives to address SDoH that are inherent or specifically built into risk-based contracts can help reduce the impact of these conditions and thus the incidence of physically and financially devastating medical events. That makes risk-based models powerful motivators for driving cost-effective care delivery—as long as practices have the insights they need to support the risks they assume.


What to consider


The benefits of improving patient outcomes from risk-based models have been well documented over the years and there is a continued increase in quantifiable results from programs that successfully navigate the new payment systems; however, many organizations have yet to fully embrace these contracts.

There are many different risk-based models for practices to consider, and most fall along a risk continuum that looks something like this:
  • Stage 1: FFS. Practices get paid for the volume of services they provide. When the number of services drops, so does reimbursement.
  • Stage 2: Pay for performance. Practices begin to get paid for managing the care of specific populations. Incentivized to identify and address contractually defined gaps in care.
  • Stage 3: Shared risk/bundled payments. Shared savings with upside risk only. Practices accept multi-year risk-sharing across a group, looking at contract management, claims, and costs.
  • Stage 4: Capitation/global payments. Practices accept full upside and downside risk, typically through multi-year arrangements that require mature capabilities.

At their core, risk-based models should inspire the flexibility to deliver care in the manner most effective for patients’ overall health. The financial model should encourage practices to offer services that usually are not reimbursed—such as care management or telehealth services, for example—as well as address SDoH.

To decide on the best risk-based arrangement for an individual practice or practice group, providers should ask themselves the following questions:
  • Which payers have progressive policies around chronic condition management, including active investment in services to address patients’ SDoH challenges?
  • Does the payer’s quality or population health reporting give you insights into non-traditional gaps such as SDoH gaps or behavioral health gaps?
  • Does the payer’s benefit coverage include holistic, person-centered care—including behavioral health?
  • Which payers have similar requirements for quality reporting that could simplify testing and scaling risk-based arrangements?
  • Does the payer’s approach to utilization management empower the practice to make decisions about its service and treatment offerings?


How to transition


Practices that successfully transition from FFS to risk-based arrangements often start small and slowly increase the percentage of their revenue tied to risk-based agreements over time. Since newer Medicare SSP models tend to reduce the window for upside risk and accelerate the engagement of downside risk, practices may want to focus first on existing targets for clinical improvement. For example, if you already have a process for ensuring patients have their annual HbA1c test or mammogram screenings, build on those programs to close any final gaps and then address more complex needs.

More often than not, practices will need to revamp some processes to make them consistent and repeatable across payer contracts, and to ensure alignment among the practice’s clinical and administrative efforts. In addition, practices and payers must strengthen their collaboration.

A commitment to data-sharing is a crucial part to executing these risk-based contracts, including understanding SDoH and improving population health. In fact, the ability to gather and access data all along the care continuum (payer, provider, patient, and potentially leveraging external data sources) is the only way to move the needle on patient outcomes. While the quality metrics measured will vary with each contract, payers should be willing to give practices supporting clinical and cost data about the patient populations impacted. This enables the practice to assess where improvements are needed, as well as provide the appropriate patient outreach.



The benefits of risk


In an FFS environment, practices that identify SDoH among their patients sometimes try to address the issues through hand-offs to social services. Sometimes the processes work well; other times, patients fall through the cracks.

Risk-based models, on the other hand, encourage practices to use quantitative and qualitative data to identify SDoH to leverage internal care management workflows to address them. Thoughtful programs need to be employed to be effective in your impact for SDoH related issues. When managed effectively—and supported by ample collaboration and data exchange—risk-based models promote better business results for practices by achieving better outcomes for patients.

Medical Practice Supplies


VIEW ALL



Manual Prescription Pad (Large - Yellow)


Manual Prescription Pad (Large - Pink)

Manual Prescription Pads (Bright Orange)

Manual Prescription Pads (Light Pink)

Manual Prescription Pads (Light Yellow)

Manual Prescription Pad (Large - Blue)

Manual Prescription Pad (Large - White)


VIEW ALL

.

Monday, October 5, 2020

Email archiving and HIPAA compliance


Email archiving is an automated process for preserving and protecting all inbound and outbound email messages (as well as attachments and metadata) so they can be accessed later. In other words, email archiving is storing emails and making them searchable.


Email archiving providers take this burden off organizations by storing emails on their servers while making them accessible to designated administrators in the organization. This is different than simply creating an email data backup. Data backups do not allow searching, so if a particular email needs to be found, it might take weeks for you to find it.


Is email archiving required for HIPAA compliance?


HIPAA delineates what covered entities need to do to maintain compliance, but it does not provide specific guidelines about how to do it. Email archiving is not explicitly mentioned anywhere in the regulations.

Under the HIPAA Security Rule, healthcare organizations have to retain electronic communications data for a minimum of six years. During this time, access and audit controls must be implemented to protect the confidentiality, integrity, and availability of electronic protected health information (ePHI) to comply with the risk analysis requirements of the Security Rule and prevent improper data modification or deletion.

Email archiving is an effective way to accomplish these HIPAA requirements.


How does email archiving work?


Email archiving solutions generally upload emails to the provider’s servers, where the emails are indexed to allow the archive to be searched. The emails are encrypted which reduces the potential for “man-in-the-middle” attacks where data is intercepted in transit.

Since the archived emails cannot be edited or deleted, they are also tamper-proof.

Service providers impose tight controls over who can access archived emails to view patient data, fulfill an audit request made by the Department of Health and Human Services (HHS), or provide email content for legal purposes.


Email archiving and eDiscovery


Electronic discovery, better known as eDiscovery, is the process in which electronically stored information (ESI) is requested, searched, located, and produced with the intent of using it in a court case as evidence, for government investigations, or as part of a Freedom of Information Act request.

If your healthcare business must conduct an audit for eDiscovery purposes, the search capabilities of an email archiver make this a vastly easier, faster, and more comprehensive process.

In addition, emails contain metadata (e.g. information about the device used to send a message or the date and time an email was sent) that is a vital part of legal evidence.


Benefits of email archiving


There are many benefits to email archiving for your healthcare business. Here are a few of the main ones.

  1. Easy storage management. Covered entities reduce their server load by allowing an email archiving providerto archive and store their emails.
  2. Business continuity. Email archiving preserves the intellectual property contained in business email and its attachments. It also eases the burden on an IT department to find lost emails.
  3. Part of disaster recovery plan. Because the data is stored on a service providers’ servers, email archiving can be part of a healthcare organization's disaster recovery plan. In the event of a ransomware attack or other catastrophic event that corrupts email data, emails and attachments can be recovered from the archive.
  4. Data theft prevention. Archiving emails also helps to prevent insider data theft or destruction by dishonest or disgruntled employees because you always have a backup in the archive.
  5. Accelerated audit response. Retaining searchable emails and attachments from all staff members means that if there is ever litigation, it will be much easier to find and produce the required emails.
  6. Disposal of PHI. In addition to privacy protection, HIPAA also features strict guidelines on how to dispose of PHI. Email archiving offers automated email retention in one centralized place. This is crucial, especially seeing as most companies have multiple departments and multiple users who are responsible for disposing of emails.

Conclusion


Email archiving is a cost-efficient safeguard that is easy to use across multiple office locations and protects both your company and patients from concerns over access, integrity, and content security issues.

Medical Practice Supplies


VIEW ALL



Manual Prescription Pad (Large - Yellow)


Manual Prescription Pad (Large - Pink)

Manual Prescription Pads (Bright Orange)

Manual Prescription Pads (Light Pink)

Manual Prescription Pads (Light Yellow)

Manual Prescription Pad (Large - Blue)

Manual Prescription Pad (Large - White)


VIEW ALL

.

Sunday, October 4, 2020

Impact of endometrioma and bilaterality on IVF/ICSI cycles

A Turkish study has found that that presence of endometrioma in patients with endometriosis negatively impacts fertility parameters, but has no effect on embryo quality, clinical pregnancy rates (PR), or live birth rates (LBR)1.

The study in the Journal of Gynecology Obstetrics and Human Reproduction also concluded bilaterality does not influence any fertility parameters or PR.

Done retrospectively, the researchers sought to investigate the effects of endometrioma and the impact of bilaterality on in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) outcomes.

A total of 159 women who underwent IVF/CSI cycles at Zekai Tahir Burak Women’s Health Education and Research Hospital in Ankara, Turkey, between March 2015 and March 2018, were recruited for the study.

Patients were divided into two groups: the study group (n = 73) of infertile women with either unilateral or bilateral ovarian endometrioma with any IVF indication; and the control group (n = 86) without endometrioma.

Basal follicle-stimulating hormone (FSH) levels and total gonadotropin doses used during ovarian stimulation were significantly higher and antral follicle count (AFC) was significantly lower in the study group compared to the control group.

But the differences in these variables between the unilateral (n = 43) and the bilateral (n = 30) endometrioma group were non-significant.

Anti-Müllerian hormone (AMH) levels for unilateral and bilateral endometrioma were also comparable: 1.4 ng/ML and 1.23 ng/mL, respectively.

However, the number of endometriomas > 4 cm was significantly higher in the bilateral than in the unilateral group.

The study also found that the number of dominant follicles at trigger day and total oocyte retrieved were significantly higher in the control group than in the study group. But when compared between the unilateral and the bilateral endometrioma group, these differences were insignificant.

Still, the number of metaphase II (MII) oocytes was significantly higher in the control group compared to the unilateral group, whereas the difference was non-significant between the control group and the bilateral group.

For all procedures, sperm was obtained via ejaculation, and there were no cycles cancelled in the control group. However, in the study group, 12 cycles were cancelled because fertilized embryos could not be procured: 6 cycles each from the unilateral and bilateral group.

There were also four patients in the study group with no dominant follicle development, two each from the unilateral and bilateral group.

In addition, there were eight total fertilization failures, four each from the two groups.

“Given the higher cancelling rates, the prognosis for patients with endometrioma seems to be worse than in patients without endometrioma,” wrote the authors.

On the other hand, the number of embryos achieved and blastocysts obtained were similar between the three groups (no laterality, unilateral and bilateral), as were rates of pregnancy, live birth, and early pregnancy loss.

There was also no statistically significant difference between the control and the unilateral groups for all grades of embryo.

However, the number of grade 2 embryos was significantly lower in the bilateral group compared to the control group. But for blastocyst and grade 1 embryo numbers, the bilateral group had comparable findings to the other two groups.

“Based on our results, we speculate that bilaterality doesn’t exert additional damage on ovarian reserve more than unilateral endometrioma does,” wrote the authors.


Reference

Yilmaz N, Ceran MU, Ugurlu EN, et al. Impact of endometrioma and bilaterality on IVF/ICSI cycles in patients with endometriosis. J Gynecol Obstet Hum Reprod. Published online June 30, 2020. doi:10.101

Medical Practice Supplies


VIEW ALL



Manual Prescription Pad (Large - Yellow)


Manual Prescription Pad (Large - Pink)

Manual Prescription Pads (Bright Orange)

Manual Prescription Pads (Light Pink)

Manual Prescription Pads (Light Yellow)

Manual Prescription Pad (Large - Blue)

Manual Prescription Pad (Large - White)


VIEW ALL

.